The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin
| Autor: | Rebecca E. Teske, Jacob E. Simmering, Linnea A. Polgreen, Philip M. Polgreen, Barry L. Carter, Alejandro P. Comellas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty hydroxychloroquine Adolescent Databases Factual Coronavirus disease 2019 (COVID-19) 030106 microbiology Azithromycin 030204 cardiovascular system & hematology Young Adult 03 medical and health sciences coronavirus infections Sex Factors 0302 clinical medicine Older patients Risk Factors Claims data Internal medicine medicine Humans Pharmacology (medical) Child Adverse effect Aged Aged 80 and over business.industry Brief Report Age Factors Infant Newborn Infant Hydroxychloroquine Middle Aged Cardiotoxicity Confidence interval COVID-19 Drug Treatment Cardiovascular Diseases Child Preschool Brief Reports Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pharmacotherapy |
| ISSN: | 1875-9114 0277-0008 |
| DOI: | 10.1002/phar.2445 |
| Popis: | Hydroxychloroquine combined with azithromycin has been investigated for activity against coronavirus disease 2019 (COVID‐19), but concerns about adverse cardiovascular (CV) effects have been raised. This study evaluated claims data to determine if risks for CV events were increased with hydroxychloroquine alone or combined with azithromycin. We identified data from 43,752 enrollees that qualified for analysis. The number of CV events increased by 25 (95% confidence interval [CI]: 8, 42, p=0.005) per 1000 people per year of treatment with hydroxychloroquine alone compared with pretreatment levels and by 201 (95% CI: 145, 256, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text